{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:37:55Z","timestamp":1791243475171,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1678,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doxorubicin-based chemotherapy after splenectomy remains the standard of care for hemangiosarcoma in dogs, but prognosis is generally poor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/objectives<\/jats:title>\n                    <jats:p>To determine clinical outcome with carboplatin chemotherapy after splenectomy compared to doxorubicin-based protocols. A secondary objective was to determine if peripheral monocyte count was associated with prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Medical data from 40 dogs with histopathologically confirmed stage I or II hemangiosarcoma treated with splenectomy and carboplatin (n\u00a0=\u00a018) or doxorubicin-based protocols (n\u00a0=\u00a022) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study. Statistical associations were assessed using the Kaplan-Meier method for survival times and log rank analysis for differences in survival time. Demographic information and survival times were obtained via medical records. Blood monocyte counts before and after surgery were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median survival times were 160\u2009days (48 to &amp;gt;559) and 139\u2009days (54-975), for dogs in the carboplatin (n\u00a0=\u00a018) and doxorubicin (n\u00a0=\u00a022) groups respectively (P\u00a0=\u00a0.82, hazards ratio [HR] [95% CI]\u00a0=\u00a01.075 [0.56-2.07]). The median survival time for dogs whose monocyte counts decreased between splenectomy and chemotherapy initiation was 265\u2009days, compared to 66\u2009days for dogs with increased monocytes (P\u00a0=\u00a0.002, HR [95% CI]\u00a0=\u00a04.17 [1.21-14.39]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Carboplatin could be considered as an alternative in cases where doxorubicin might be contraindicated. Increasing postoperative peripheral monocyte counts might be associated with a poorer prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16212","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T21:35:36Z","timestamp":1625520936000},"page":"1929-1934","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-2637","authenticated-orcid":false,"given":"Erica A.","family":"Faulhaber","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center , Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Janik","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center , Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7767","authenticated-orcid":false,"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center , Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"4","key":"2026020922170802700_jvim16212-bib-0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012)","volume":"247","author":"Wendelburg","year":"2015","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922170802700_jvim16212-bib-0002","first-page":"679","article-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"Thamm","year":"2013","edition":"5"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0003","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00266.x","article-title":"A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma","volume":"9","author":"Teske","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0004","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1939-1676.1993.tb01033.x","article-title":"Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide","volume":"7","author":"Sorenmo","year":"1993","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0006","first-page":"237","article-title":"Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study","volume":"54","author":"Kahn","year":"2013","journal-title":"Can Vet J"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1939-1676.1991.tb00923.x","article-title":"Hemostatic abnormalities in dogs with hemangiosarcoma","volume":"5","author":"Hammer","year":"1991","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.5326\/JAAHA-MS-6540","article-title":"Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma","volume":"53","author":"Matsuyama","year":"2017","journal-title":"J Am Anim Hosp Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/vco.12139","article-title":"Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma","volume":"15","author":"Finotello","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/vco.12193","article-title":"A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma","volume":"15","author":"Finotello","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0011","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jsap.12926","article-title":"The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma","volume":"60","author":"Alexander","year":"2019","journal-title":"J Small Anim Pract"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0013","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1207936","article-title":"Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells","volume":"23","author":"Kluza","year":"2004","journal-title":"Oncogene"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1939-1676.1993.tb01013.x","article-title":"Pharmacokinetic and phase I evaluation of carboplatin in dogs","volume":"7","author":"Page","year":"1993","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1939-1676.1996.tb02031.x","article-title":"Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)","volume":"10","author":"Bergman","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/vco.12069","article-title":"Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial","volume":"14","author":"Skorupski","year":"2016","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0017","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1939-1676.1997.tb00465.x","article-title":"Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder","volume":"11","author":"Chun","year":"1997","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/jvim.12533","article-title":"Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs","volume":"29","author":"Allstadt","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1476-5810.2005.00065.x","article-title":"Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of canine model of human head and neck squamous cell carcinoma","volume":"3","author":"de Vos","year":"2005","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/vco.12068","article-title":"Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs","volume":"14","author":"Wouda","year":"2016","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00480169.2012.699433","article-title":"Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival","volume":"61","author":"Brockley","year":"2013","journal-title":"N Z Vet J"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0022","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","article-title":"Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000)","volume":"218","author":"Rassnick","year":"2001","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0023","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.20141836","article-title":"CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages","volume":"212","author":"Kitamura","year":"2015","journal-title":"J Exp Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10555-006-9027-x","article-title":"CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases","volume":"25","author":"Craig","year":"2006","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0025","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1939-1676.2010.0591.x","article-title":"Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma","volume":"24","author":"Sottnik","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1476-5829.2010.00235.x","article-title":"Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma","volume":"9","author":"Perry","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0027","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/vco.12272","article-title":"Role of monocyte recruitment in hemangiosarcoma metastasis in dogs","volume":"15","author":"Regan","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0028","first-page":"865","article-title":"Anthracycline cardiomyopathy monitored by morphologic changes","volume":"62","author":"Billingham","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvim.12525","article-title":"P-glycoprotein mediated drug interactions in animals and humans with cancer","volume":"29","author":"Mealey","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5326\/15473317-36-1-13","article-title":"Carboplatin","volume":"36","author":"Fox","year":"2000","journal-title":"J Am Anim Hosp Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0031","first-page":"e1","article-title":"Haemangiosarcoma of the os penis in a dog: the most common neoplasm of the canine penis","volume":"85","author":"Burchell","year":"2014","journal-title":"J S Afr Vet Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0032","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1939-1676.2007.0017.x","article-title":"Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study","volume":"22","author":"Kisseberth","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0033","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2460\/javma.251.5.559","article-title":"Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014)","volume":"251","author":"Moore","year":"2017","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0034","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004)","volume":"231","author":"Kim","year":"2007","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020922170802700_jvim16212-bib-0035","first-page":"43","article-title":"Retrospective comparison of first-line adjuvant anthracycline vs metronomic-based chemotherapy protocols in the treatment of stage I and II canine splenic haemangiosarcoma","volume":"18","author":"Treggiari","year":"2019","journal-title":"Vet Comp Oncol"}],"updated-by":[{"DOI":"10.1111\/jvim.16287","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000}}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1929\/66651931\/jvim16212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1929\/66651931\/jvim16212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:26:59Z","timestamp":1770694019000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/4\/1929\/8446969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16212","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"2021-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}